SEC Comment Letter 0000000000-23-002789 to Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc.
Date: March 21, 2023 · CIK: 0001875558 · Accession: 0000000000-23-002789
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270657
Letter
United States securities and exchange commission logo March 21, 2023 Ron Bentsur, M.B.A. Chairman, President and Chief Executive Officer Nuvectis Pharma, Inc. 1 Bridge Plaza Suite 275 Fort Lee, NJ 07024 Re:Nuvectis Pharma, Inc. Registration Statement on Form S-3 Filed March 17, 2023 File No. 333-270657 Dear Ron Bentsur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew W. Mamak, Esq.
Show Raw Text
United States securities and exchange commission logo
March 21, 2023
Ron Bentsur, M.B.A.
Chairman, President and Chief Executive Officer
Nuvectis Pharma, Inc.
1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
Re:Nuvectis Pharma, Inc.
Registration Statement on Form S-3
Filed March 17, 2023
File No. 333-270657
Dear Ron Bentsur:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew W. Mamak, Esq.